Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study days 0, 1, 2, 9, 16, and 23.
Phase 2b/3, randomized, double-blind, multicenter, placebo-controlled study evaluating the safety, efficacy and pharmacokinetics (PK) of pagibaximab (100 mg/kg/dose) in comparison to placebo for the prevention of staphylococcal sepsis in VLBW infants (600 -1200 grams). Subjects monitored for treatment related adverse events and tolerability to infusion of study drug. Neonatal sepsis will be assessed in the presence of clinical signs and symptoms and one blood culture positive for S. aureus or two blood cultures positive for Coagulase Negative Staphylococci (CoNS). The study period will be 35 days after the first dose or until, death, discharge, or transfer, whichever occurs first.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,579
Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
Biosynexus Incorporated
Gaithersburg, Maryland, United States
The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.
Safety and efficacy
Time frame: 35 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.